X

Trial Profile

Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efavirenz (Primary) ; Emtricitabine; Isoniazid; Lamivudine; Rifampicin; Tenofovir; Zidovudine
Indications HIV-1 infections
Focus Pharmacokinetics

Most Recent Events

06 Aug 2018 Status changed from recruiting to completed, according to results published in the Clinical Infectious Diseases.
06 Aug 2018 Results published in the Clinical Infectious Diseases.
26 Jul 2017 Results of effects of efavirenz in women living with HIV (WLWH) during third trimester of pregnancy and post-partum (n=22) presented at the 9th International AIDS Society Conference on HIV Science

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com